Rare diseases
Investigational molecules
Locations
Back to Poland3 clinical trials in DO NOT EDIT, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PolandBadaniaKliniczne.pl(opens in a new tab)Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations
PolandNeoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer
PolandPhase 1/2 Study of VRN110755 to Assess Safety, Dose and Efficacy in Patients with EGFR‑mutant Non‑Small Cell Lung Cancer
PolandThe busiest research cities in the country
What the registry says about research in the country
In the city, investigators are conducting early‑stage studies aimed at establishing the safety and tolerability of a novel agent, TER-2013, both as a single treatment and in combination with estrogen‑receptor targeting drugs.
The trials are actively recruiting and seek to accelerate therapeutic options for patients with diverse solid‑tumor profiles.
A separate investigation focuses on neoadjuvant personalized therapy that pairs sacituzumab govitecan with pembrolizumab, comparing outcomes to standard chemotherapy in stage II‑III disease.
This recruiting study aims to improve cure rates for patients with this aggressive breast cancer subtype.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
